Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Ph...( Cardio-diagnostic compan...)

Cardio-diagnostic company adds new line of heart disease and diabetes tests to complement advanced cholesterol profile

BIRMINGHAM, Ala., April 20 /PRNewswire/ -- Atherotech, Inc. today announced it will be exhibiting its VAP(R) Cholesterol Test in booth #912 at Internal Medicine 2009, the annual scientific meeting of the American College of Physicians (ACP). The conference takes place April 23-25, 2009, at the Pennsylvania Convention Center in Philadelphia.

Used in more than 100 clinical trials, including the Heredity and Phenotype Intervention (HAPI) Heart Study recently published in Science, the VAP (Vertical Auto Profile) Test is the most accurate cholesterol test available today.

The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard test and can identify a far great number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The test identifies markers for metabolic syndrome, a precursor for diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

The VAP Test provides physicians and researchers with direct measurement of LDL, HDL and all relevant subclasses, non-HDL and emerging risk factors such as Lp(a), remnants and small dense LDL.

Atherotech recently announced the addition of more than a dozen tests for patients at intermediate to high risk of cardiometabolic diseases. The new test panels are available immediately and also include homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D, fibrinogen and insulin. The tests can be ordered individually, or bundled as part of a custom risk profile that may also include the VAP Test.

Atherotech representatives will be available to discuss the VAP Cholesterol Te
'/>"/>